Clinical Trial

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Study acronym: DESCENT-1
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-18; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-07-10
Trial Details
NCT Number NCT06885424
Lead Sponsor A2 Biotherapeutics Inc.
Conditions Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Pancreatic Cancer, NSCLC +7 more
Enrollment 400 participants
Start Date 2025-07-31
Primary Completion 2030-03-31 (estimated)
Study Completion 2040-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-20